x

Posted 12 December, 2023

MUSTANG BIO, INC. appointed new CEO

CEO Change detected for ticker Nasdaq:MBIO in a 8-K filed on 12 December, 2023.


  On December 11, 2023, the Board of Directors of the Company (the "Board") appointed Manuel Litchman, M.D., President and Chief Executive Officer of the Company, as the Company's Interim Chief Financial Officer, effective immediately.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of MUSTANG BIO, INC.
Health Care/Life Sciences • Biotechnology
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Worcester, MA.
Market Cap
$13.6M
View Company Details
MUSTANG BIO, INC. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On December 8, 2023, Eliot Lurier, the Interim Chief Financial Officer of Mustang Bio, Inc. (the "Company" or "Mustang"), passed away unexpectedly. Mr. Lurier had served as the Company's Interim Chief Financial Officer since April 2022.


On December 11, 2023, the Board of Directors of the Company (the "Board") appointed Manuel Litchman, M.D., President and Chief Executive Officer of the Company, as the Company's Interim Chief Financial Officer, effective immediately. Dr. Litchman, age 69, has been the Company's President and Chief Executive Officer, and a member of the Company's Board of Directors, since April 2017.


Also on December 11, 2023, the Board appointed Peter Carney, Controller of the Company, as the Company's Interim Chief Accounting Officer, effective immediately. Mr. Carney, age 37, has been the Controller of the Company since August 2021. Prior to joining the Company, from August 2017 to August 2021, Mr. Carney was an Accounting Manager at Staples, Inc., a multinational business and consumer goods retailer, focused on consolidations and the integrations of acquired businesses. Prior to this, Mr. Carney served as Assistant Controller at General Electric, U.S. Life Sciences. He began his career in the assurance practice at PricewaterhouseCoopers, LLP. Mr. Carney holds an M.B.A and M.S. in Accounting from Northeastern University and is a Certified Public Accountant in Massachusetts.


There were no arrangements or understandings between either Dr. Litchman or Mr. Carney and any other person pursuant to which Dr. Litchman and Mr. Carney were selected as officers. Neither Dr. Litchman nor Mr. Carney have any family relationships subject to disclosure under Item 401(d) of Regulation S-K or any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. The Company has not entered into, adopted or commenced any new, or amended any existing compensation plans, arrangements, or employment agreements with Dr. Litchman or Mr. Carney in connection with these appointments.